Comparing Werewolf Therapeutics (NASDAQ:HOWL) & Oncocyte (NASDAQ:IMDX)

Werewolf Therapeutics (NASDAQ:HOWL) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Werewolf Therapeutics and Oncocyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	N/A	N/A
Oncocyte	N/A	N/A	N/A

Insider and Institutional Ownership

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of Oncocyte shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Werewolf Therapeutics has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Valuation and Earnings

This table compares Werewolf Therapeutics and Oncocyte”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$21.00 million	2.41	-$36.94 million	($0.76)	-1.37
Oncocyte	$1.67 million	61.92	-$48.76 million	($1.49)	-2.12

Werewolf Therapeutics has higher revenue and earnings than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Werewolf Therapeutics and Oncocyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1	3	2	1	2.43
Oncocyte	1	0	2	0	2.33

Werewolf Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 284.62%. Oncocyte has a consensus target price of $10.50, suggesting a potential upside of 232.28%. Given Werewolf Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Oncocyte.

Summary

Werewolf Therapeutics beats Oncocyte on 9 of the 11 factors compared between the two stocks.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.